FDA Cautious On Forced Rx-To-OTC Switches
This article was originally published in The Tan Sheet
Executive Summary
While FDA has concluded internally it has the authority to determine whether a drug should be Rx or OTC, the agency is being cautious about an official announcement of its position
You may also be interested in...
FDA-Initiated OTC Switches Could Be Based On Foreign Data – McClellan
FDA may rely on a drug's foreign OTC marketing experience to determine whether an Rx product should be switched OTC in the U.S. without sponsor consent, Commissioner Mark McClellan, MD/PhD, said at a Manhattan Institute roundtable discussion for buyside analysts May 16
FDA-Initiated OTC Switches Could Be Based On Foreign Data – McClellan
FDA may rely on a drug's foreign OTC marketing experience to determine whether an Rx product should be switched OTC in the U.S. without sponsor consent, Commissioner Mark McClellan, MD/PhD, said at a Manhattan Institute roundtable discussion for buyside analysts May 16
FDA-Initiated OTC Switches Could Be Based On Foreign Data – McClellan
FDA may rely on a drug's foreign OTC marketing experience to determine whether an Rx product should be switched OTC in the U.S. without sponsor consent, Commissioner Mark McClellan, MD/PhD, said at a Manhattan Institute roundtable discussion for buyside analysts May 16